platinum has been researched along with Stomach Neoplasms in 54 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (3.70) | 18.7374 |
| 1990's | 7 (12.96) | 18.2507 |
| 2000's | 5 (9.26) | 29.6817 |
| 2010's | 22 (40.74) | 24.3611 |
| 2020's | 18 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bu, L; Chen, J; Feng, Y; Hao, J; Ma, T; Ning, J; Wang, R; Wu, L; Wu, Z; Xie, M; Xu, H; Zhang, C; Zhang, Y | 1 |
| An, M; Heo, YJ; Kang, WK; Kim, KM; Kim, R; Kim, ST; Kim, TJ; Klempner, SJ; Lee, H; Lee, J; Lee, SY; Mehta, A; Min, BH; Moon, J; Park, WY; Rha, SY | 1 |
| Kang, YK; Koo, DH; Lee, MY; Moon, MS; Ryu, MH | 1 |
| Cho, MS; Cho, SY; Huh, YJ; Lee, JH; Lee, KE | 1 |
| Hu, Y; Tang, C; Wei, X; Yuwen, D; Zhang, J; Zhang, W; Zhu, X; Zhu, Y | 1 |
| Boku, N; Chin, K; Ichimura, T; Kadowaki, S; Kitano, S; Kudo, T; Liu, J; Mitani, S; Muro, K; Ooki, A; Sakai, D; Satoh, T; Takashima, A; Thai, D; Yamaguchi, K; Zavodovskaya, M | 1 |
| Albers, D; Kasper, S; Lahner, H; Markus, P; Mende, B; Mika, S; Reis, H; Rosery, V; Schmid, KW; Schuler, M; Schumacher, B; Siveke, JT; Stuschke, M; Treckmann, J; Wiesweg, M | 1 |
| Li, C; Li, X; Shen, L; Wang, S; Wang, T; Zhai, J | 1 |
| Brossart, P; Feldmann, G; Gonzalez-Carmona, MA; Jafari, A; Kalff, JC; Köksal, M; Lingohr, P; Mahn, R; Mańczak, A; Möhring, C; Monin, MB; Sadeghlar, F; Sarria, GR; Sommer, N; Strassburg, CP; Timotheou, A; Toma, M; Zhou, T | 1 |
| Bang, YJ; Borg, C; Calvo, M; Cervantes, A; Ciardiello, F; Dvorkin, M; Gupta, N; Kannourakis, G; Kawakami, H; Lopez, CD; Metges, JP; Muro, K; Pelham, RJ; Sánchez Ruiz, A; Shen, L; Strickland, AH; Wei, J; Zhu, Z | 1 |
| Chen, X; Ding, H; Ding, J; Luo, D; Wang, L; Wei, Y; Xiong, Y; Yi, F; Zhang, W | 1 |
| Bai, Z; Pang, K; Song, J; Zhang, Z | 1 |
| Luo, Y; Pei, S; Xiao, Y; Xu, J; Zhu, X | 1 |
| Asai, R; Harada, K; Hattori, T; Honma, R; Kuraoka, K; Maruyama, R; Morii, E; Murai, J; Ohdan, H; Sakamoto, N; Sasaki, AT; Takashima, T; Tanabe, K; Taniyama, D; Thang, PQ; Ukai, S; Yasui, W; Yasumoto, M | 1 |
| Eguchi, N; Ikeshima, M; Kawasaki, N; Saitoh, Y | 1 |
| Fujisaki, M; Fujita, S; Futawatari, N; Kikuchi, Y; Mitsumori, N; Murakami, M; Nagaoka, S; Oshima, Y; Otsuka, K; Seto, Y; Shimada, H; Yajima, S; Yamashita, H | 1 |
| Cho, H; Kang, YK; Kim, HD; Lee, HE; Ryu, MH | 1 |
| Bozkaya, Y; Demirci, NS; Erdem, GU; Ozdemir, NY; Yazici, O; Zengin, N | 1 |
| Chen, R; Ding, H; Fen, Y; Fu, X; Ji, X; Mao, X; Ren, K; Shan, Y; Wu, X; Zhou, F | 1 |
| Chen, F; Gou, S; Jin, X; Zhao, J | 1 |
| Fujikawa, K; Hatachi, Y; Kato, T; Kotaka, M; Sagawa, T; Satake, H; Tsuji, A; Yasui, H | 1 |
| Dai, Q; Li, C; Liu, B; Pan, J; Wang, Z; Xiang, Z | 1 |
| Asensio, E; Azkarate, A; Cano, JM; Carmona-Bayonas, A; Cerdà, P; Custodio, A; Gallego, J; Garrido, M; Hernández, R; Hurtado, A; Iglesia, L; Jiménez-Fonseca, P; Lacalle, A; Limón, ML; Macías, I; Mangas, M; Martín-Carnicero, A; Martínez de Castro, E; Martínez-Torrón, A; Ramchandani, A; Reguera, P; Sánchez, A; Sánchez-Bayonas, R; Sánchez-Cánovas, M; Serrano, R; Visa, L; Viúdez, A | 1 |
| Joh, T; Kamiya, T; Kataoka, H; Kawamoto, K; Mizoshita, T; Mori, Y; Ohi, H; Shibahara, T; Tanaka, M; Tanida, S; Yano, S | 1 |
| Guan, W; Liu, B; Qian, X; Shen, J; Wang, H; Wei, J; Yu, L; Yue, G; Zou, Z | 1 |
| Boku, N; Esaki, T; Fujitani, K; Hamamoto, Y; Hironaka, S; Hyodo, I; Morita, S; Moriwaki, T; Nagase, M; Nishina, T; Okamoto, I; Shimodaira, H; Sugimoto, N; Tokunaga, S; Tsuda, M; Tsumura, T; Ueda, S; Ura, T; Yamaguchi, K; Yasui, H | 1 |
| Ando, T; Fujinami, H; Horikawa, N; Hosokawa, A; Kajiura, S; Kobayashi, T; Mihara, H; Minemura, M; Nishikawa, J; Note, M; Ogawa, K; Sugiyama, T; Terada, M; Ueda, A; Yabushita, K; Yoshita, H | 1 |
| Bearzi, I; Bianconi, M; Bittoni, A; Cascinu, S; Cecchini, L; Del Prete, M; Faloppi, L; Giampieri, R; Mandolesi, A; Pistelli, M; Scartozzi, M | 1 |
| Bai, Y; Chu, YP; Gong, JF; Li, J; Li, Y; Shen, L; Zhang, XT | 1 |
| Ma, J; Wang, SY; Xu, J; Zhou, JW; Zong, HT | 1 |
| Dai, Q; Guan, QL; Jiang, L; Qian, XK; Wang, YF; Wei, KK; Wei, YY | 1 |
| Peng, X; Qi, Y; Wang, Q; Wang, Y; Yao, A; Ye, R; Zhou, F | 1 |
| Fang, W; Jiang, H; Mao, C; Qian, J; Xu, N; Zhang, X; Zhao, P; Zheng, Y | 1 |
| Ding, LH; Gao, S; Li, CB; Liu, ZY; Wang, ZY; Wu, XL; Zhou, J | 1 |
| Bu, Z; Hu, Y; Ji, J; Jia, Y; Li, S; Li, Z; Miao, R; Shan, F; Wu, A; Xiao, A; Xing, X; Xing, Z; Xue, K; Zhang, L | 1 |
| Kang, YK; Lee, CW; Lee, JK; Na, YS; Park, SJ; Park, SR; Park, YS; Ryoo, BY; Ryu, MH; Seo, S | 1 |
| Fareed, KR; Ilyas, M; Kaye, PV; Lobo, DN; Madhusudan, S; Parsons, SL; Soomro, IN | 1 |
| Ling, Y; Liu, BR; Liu, YP; Zhang, YP | 1 |
| Kang, WK; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS; Yi, JH; Yim, DS | 1 |
| Chi, Y; Cui, CX; Li, YS; Lü, N; Song, Y; Sun, YK; Wang, JW; Yang, L; Yuan, XH; Zhang, W; Zhou, AP | 1 |
| Bang, YJ; Choi, IS; Han, SW; Im, SA; Kang, EJ; Kim, JH; Kim, JS; Kim, JW; Kim, TY; Kim, YJ; Lee, JS; Lee, KW; Oh, DY | 1 |
| Kitajima, M; Kubota, T; Kumai, K; Maeda, S; Otani, Y; Saikawa, Y; Sugiura, T | 1 |
| Chang, HM; Choi, SJ; Kang, YK; Kim, TW; Kim, WK; Lee, JS; Park, YH; Ryu, BY | 1 |
| Chen, XZ; Gao, WQ; Hou, SQ; Liu, WP; Liu, Y; Lou, LG; Ye, QS; Yu, Y | 1 |
| Beijnen, JH; Boot, H; Brouwers, EE; Cats, A; Pluim, D; Rosing, H; Schellens, JH; Tibben, MM | 1 |
| Bilynskyĭ, BT; Shparyk, IaV | 1 |
| Arimori, M; Furukawa, T; Ishibiki, K; Isobe, Y; Kase, S; Kubota, T; Kuo, TH; Saikawa, Y; Tanino, H; Watanabe, M | 1 |
| Furukawa, T; Ishibiki, K; Kase, S; Kitajima, M; Kubota, T; Kuo, TH; Saikawa, Y; Tanino, H | 1 |
| Chung, YS; Maeda, K; Nakata, B; Nitta, A; Onoda, N; Sawada, T; Sowa, M; Yashiro, M | 1 |
| Ikeda, K; Ishida, K; Iwaya, T; Kawamura, H; Koeda, K; Maesawa, C; Saito, K; Sato, N; Takagane, A; Takiyama, I; Terashima, M; Yoshinari, H | 1 |
| Araki, K; Beppu, T; Hamada, S; Kobayashi, M; Matsuura, K; Ohmi, K; Sugimoto, T; Takano, A; Yamamoto, H | 1 |
| Hirabayashi, K; Oguma, T; Okada, E; Shimamura, K | 1 |
| Daidoh, T; Itoh, A; Sawai, K; Seiki, K; Shioaki, Y; Taniguchi, H; Tsukuda, N; Yamaguchi, T; Yamane, T; Yokota, T | 1 |
| Dohnalová, J; Dostálová, O; Drobník, J; Fiserová, J; Holík, F | 1 |
6 review(s) available for platinum and Stomach Neoplasms
| Article | Year |
|---|---|
The optimal neoadjuvant chemotherapy regimen for locally advanced gastric and gastroesophageal junction adenocarcinoma: a systematic review and Bayesian network meta-analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Chemotherapy, Adjuvant; Esophagogastric Junction; Fluorouracil; Humans; Neoadjuvant Therapy; Network Meta-Analysis; Platinum; Stomach Neoplasms; Taxoids | 2022 |
Comparison of Platinum/S-1 and Platinum/5-Fluorouracil as First-Line Chemotherapy for Advanced Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis Based on Randomized Controlled Trials.
Topics: Antineoplastic Agents; Coordination Complexes; Disease-Free Survival; Drug Combinations; Drug Therapy, Combination; Esophagogastric Junction; Fluorouracil; Gastrointestinal Neoplasms; Humans; Neoplasm Staging; Oxonic Acid; Platinum; Proportional Hazards Models; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2020 |
Pharmacogenetic role of XRCC1 polymorphisms on the clinical outcome of gastric cancer patients with platinum-based chemotherapy: a systematic review and meta-analysis.
Topics: Alleles; Antineoplastic Agents; DNA-Binding Proteins; Genotype; Humans; Odds Ratio; Platinum; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Prognosis; Stomach Neoplasms; Treatment Outcome; X-ray Repair Cross Complementing Protein 1 | 2014 |
The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; DNA-Binding Proteins; Endonucleases; Humans; Immunohistochemistry; Odds Ratio; Platinum; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2014 |
Predictive value of excision repair cross-complementation group 1 expression for platinum-based chemotherapy and survival in gastric cancer: a meta-analysis.
Topics: DNA-Binding Proteins; Endonucleases; Humans; Immunohistochemistry; Platinum; Predictive Value of Tests; Publication Bias; Real-Time Polymerase Chain Reaction; Stomach Neoplasms | 2014 |
[Effectiveness of platinum drugs in the treatment of gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Platinum; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Rate | 1993 |
10 trial(s) available for platinum and Stomach Neoplasms
| Article | Year |
|---|---|
A phase 1b study of andecaliximab in combination with S-1 plus platinum in Japanese patients with gastric adenocarcinoma.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Humans; Japan; Matrix Metalloproteinase 9; Oxaliplatin; Platinum; Stomach Neoplasms | 2022 |
Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: Phase 2 study results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Fluorenes; Humans; Platinum; Progression-Free Survival; Stomach Neoplasms | 2023 |
Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Drug Administration Schedule; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Platinum; Ramucirumab; Salvage Therapy; Stomach Neoplasms; Survival Analysis; Taxoids | 2018 |
Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 tria
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Paclitaxel; Platinum; Prospective Studies; Stomach Neoplasms; Treatment Failure; Treatment Outcome | 2013 |
A phase II study of triweekly paclitaxel and capecitabine combination therapy in patients with fluoropyrimidine-platinum-resistant metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Platinum; Pyrimidines; Stomach Neoplasms | 2013 |
Biweekly S-1 plus paclitaxel (SPA) as second-line chemotherapy after failure from fluoropyrimidine and platinum in advanced gastric cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asian People; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Injections, Intravenous; Male; Middle Aged; Neutropenia; Oxonic Acid; Paclitaxel; Platinum; Stomach Neoplasms; Tegafur; Treatment Outcome | 2014 |
Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Female; Fluorouracil; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Platinum; Pyrroles; Salvage Therapy; Stomach Neoplasms; Sunitinib; Survival Rate; Taxoids; Tissue Distribution; Treatment Outcome; Young Adult | 2012 |
[Phase II clinical trial of docetaxel, platinum and S-1 for advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Platinum; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2012 |
Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Drug Administration Schedule; Endpoint Determination; Female; Fluorouracil; Humans; Male; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Platinum; Stomach Neoplasms | 2005 |
Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Kidney; Male; Middle Aged; Platinum; Stomach Neoplasms | 1998 |
38 other study(ies) available for platinum and Stomach Neoplasms
| Article | Year |
|---|---|
Survival outcomes of adjuvant taxanes, platinum plus fluoropyrimidines versus platinum and fluoropyrimidines for gastric cancer patients after D2 gastrectomy: a retrospective propensity score-matched analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Gastrectomy; Humans; Neoplasm Staging; Platinum; Prognosis; Propensity Score; Retrospective Studies; Stomach Neoplasms; Taxoids | 2021 |
Early Tumor-Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Genomics; Humans; Platinum; Stomach Neoplasms; Tumor Microenvironment | 2022 |
New prognostic model for patients with advanced gastric cancer: Fluoropyrimidine/platinum doublet for first-line chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Neoplasm Recurrence, Local; Platinum; Prognosis; Retrospective Studies; Stomach Neoplasms | 2021 |
Comparative analysis of cancer gene mutations using targeted sequencing in matched primary and recurrent gastric cancers after chemotherapy.
Topics: Fluorouracil; Genes, Neoplasm; Humans; Mutation; Platinum; Stomach Neoplasms | 2022 |
Plasma thioredoxin reductase: a potential diagnostic biomarker for gastric cancer.
Topics: Biomarkers, Tumor; Fluorouracil; Humans; Platinum; Stomach Neoplasms; Thioredoxin Reductase 1 | 2022 |
Identification of a new prognostic score for patients with high-grade metastatic GEP-NEN treated with palliative chemotherapy.
Topics: Etoposide; Gastrointestinal Neoplasms; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Platinum; Prognosis; Retrospective Studies; Stomach Neoplasms | 2023 |
Perioperative therapy with FLOT4 significantly increases survival in patients with gastroesophageal and gastric cancer in a large real-world cohort.
Topics: Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Platinum; Prospective Studies; Retrospective Studies; Stomach Neoplasms | 2023 |
miR-15a-5p targets PHLPP2 in gastric cancer cells to modulate platinum resistance and is a suitable serum biomarker for oxaliplatin resistance.
Topics: Biomarkers, Tumor; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; MicroRNAs; Oxaliplatin; Phosphoprotein Phosphatases; Platinum; Stomach Neoplasms | 2020 |
Combined chemotherapy of platinum and fluorouracil promotes T cell-mediated antitumor immunity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Disease Models, Animal; Drug Therapy, Combination; Fluorouracil; Humans; Melanoma; Mice, Inbred C57BL; Neoplasms; NF-kappa B p50 Subunit; Oxaliplatin; Platinum; Stomach Neoplasms; T-Lymphocyte Subsets; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Helper-Inducer | 2021 |
Schlafen 11 predicts response to platinum-based chemotherapy in gastric cancers.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Humans; Nuclear Proteins; Platinum; Prognosis; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2021 |
Combined treatment with dissolved hydrogen molecule and platinum nanocolloid exerts carcinostatic/carcinocidal effects by increasing hydrogen peroxide generation and cell death in the human gastric cancer cell line NUGC-4.
Topics: Cell Death; Cell Line, Tumor; Humans; Hydrogen; Hydrogen Peroxide; Nanocomposites; Platinum; Stomach Neoplasms | 2021 |
Taxane-based versus platinum-based chemotherapy in early recurrent gastric cancer after radical surgery with S-1 adjuvant chemotherapy: A multi-institutional retrospective analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Humans; Neoplasm Recurrence, Local; Platinum; Retrospective Studies; Stomach Neoplasms; Taxoids | 2022 |
Prognostic value of natural killer cell activity for patients with HER2 + advanced gastric cancer treated with first-line fluoropyrimidine-platinum doublet plus trastuzumab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Killer Cells, Natural; Male; Middle Aged; Platinum; Prognosis; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2022 |
5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as a third-line chemotherapy treatment in metastatic gastric cancer, after failure of fluoropyrimidine, platinum, anthracycline, and taxane.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Female; Fluorine; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Patient Safety; Platinum; Pyrimidines; Stomach Neoplasms; Taxoids; Treatment Outcome | 2018 |
The prognostic role of MAC30 in advanced gastric cancer patients receiving platinum-based chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Female; Gene Expression; Humans; Kaplan-Meier Estimate; Male; Membrane Proteins; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Platinum; Prognosis; RNA, Messenger; Stomach Neoplasms; Treatment Outcome | 2017 |
DN604: A platinum(II) drug candidate with classic SAR can induce apoptosis via suppressing CK2-mediated p-cdc25C subcellular localization in cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carboplatin; cdc25 Phosphatases; Cell Cycle Checkpoints; Cell Proliferation; Checkpoint Kinase 2; Colonic Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Platinum; Stomach Neoplasms; Structure-Activity Relationship; Subcellular Fractions; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Prediction of platinum-resistance patients of gastric cancer using bioinformatics.
Topics: Computational Biology; Databases, Genetic; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Male; NADH Dehydrogenase; Oxidoreductases Acting on Sulfur Group Donors; Platinum; Repressor Proteins; Stomach Neoplasms | 2019 |
Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Decision-Making; Female; Humans; Maintenance Chemotherapy; Male; Middle Aged; Platinum; Progression-Free Survival; Pyrimidines; Registries; Stomach Neoplasms; Survival Rate; Time Factors; Young Adult | 2020 |
Anti-cancer effects of newly developed chemotherapeutic agent, glycoconjugated palladium (II) complex, against cisplatin-resistant gastric cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Proliferation; Cisplatin; DNA Breaks, Double-Stranded; Drug Resistance, Neoplasm; Female; Gene Expression; Genes, p16; Glycoconjugates; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Palladium; Platinum; Stomach Neoplasms; Up-Regulation | 2013 |
Synergistic anticancer effects of polyphyllin I and evodiamine on freshly-removed human gastric tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Confidence Intervals; Diosgenin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Platinum; Quinazolines; RNA, Messenger; Stomach Neoplasms | 2013 |
Non-randomized comparison between irinotecan plus mitomycin C and irinotecan alone in patients with advanced gastric cancer refractory to fluoropyrimidine and platinum.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Neoplasm Staging; Platinum; Prognosis; Salvage Therapy; Stomach Neoplasms; Survival Rate | 2013 |
Clinical evidence for three distinct gastric cancer subtypes: time for a new approach.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Male; Middle Aged; Platinum; Stomach Neoplasms; Treatment Outcome | 2013 |
Genetic polymorphisms of DNA repair pathways influence the response to chemotherapy and overall survival of gastric cancer.
Topics: Adult; Aged; Cell Cycle Proteins; DNA Repair; DNA-Binding Proteins; Endonucleases; Female; Genotype; Humans; Male; Middle Aged; Nuclear Proteins; Platinum; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Prognosis; Rad51 Recombinase; Stomach Neoplasms; Survival Analysis; Xeroderma Pigmentosum Group D Protein | 2015 |
ABCC2-24C > T polymorphism is associated with the response to platinum/5-Fu-based neoadjuvant chemotherapy and better clinical outcomes in advanced gastric cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Genotype; Humans; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoadjuvant Therapy; Platinum; Polymorphism, Single Nucleotide; Stomach Neoplasms | 2016 |
Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Gene Amplification; Gene Dosage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Platinum; Prognosis; Proportional Hazards Models; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 2; Stomach Neoplasms; Treatment Outcome; Young Adult | 2017 |
Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Platinum; Remission Induction; Retrospective Studies; Single-Blind Method; Stomach Neoplasms; Treatment Outcome | 2009 |
[Predictive values of platinum-related gene polymorphisms in gastric cancer patients on oxaliplatin-based adjuvant chemotherapy].
Topics: Chemotherapy, Adjuvant; DNA-Binding Proteins; Endonucleases; Female; Genotype; Glutathione S-Transferase pi; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Platinum; Polymorphism, Single Nucleotide; Predictive Value of Tests; Stomach Neoplasms; X-ray Repair Cross Complementing Protein 1 | 2011 |
Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Carcinoma, Signet Ring Cell; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2013 |
Docetaxel enhances the cytotoxicity of cisplatin to gastric cancer cells by modification of intracellular platinum metabolism.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cisplatin; Docetaxel; Drug Interactions; Humans; Platinum; Stomach Neoplasms; Taxoids; Tumor Cells, Cultured; Up-Regulation | 2004 |
Synthesis and in vitro cytotoxicity of novel lipophilic (diamine)platinum(II) complexes of salicylate derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Diamines; Drug Screening Assays, Antitumor; Humans; Liposomes; Lung Neoplasms; Platinum; Salicylates; Solubility; Solvents; Spectrum Analysis; Stomach Neoplasms | 2007 |
Inductively coupled plasma mass spectrometric analysis of the total amount of platinum in DNA extracts from peripheral blood mononuclear cells and tissue from patients treated with cisplatin.
Topics: Antineoplastic Agents; Cisplatin; DNA Adducts; Humans; Isotopes; Leukocytes, Mononuclear; Mass Spectrometry; Platinum; Stomach Neoplasms | 2008 |
Synergistic antitumor activity of combination chemotherapy with mitomycin C and cisplatin against human gastric cancer xenografts in nude mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Synergism; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitomycin; Platinum; Stomach Neoplasms; Time Factors; Transplantation, Heterologous | 1994 |
Synergistic antitumor activity of mitomycin C and cisplatin against gastric cancer cells in vitro.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Synergism; Humans; Mitomycin; Platinum; Stomach Neoplasms; Tumor Cells, Cultured | 1993 |
Establishment of a cisplatin-resistant gastric carcinoma cell line OCUM-2M/DDP.
Topics: Antineoplastic Agents; Cisplatin; Drug Resistance; Glutathione; Humans; Platinum; Stomach Neoplasms; Tumor Cells, Cultured | 1997 |
[Intraoperative local infusion chemotherapy (ILIC) for gastric cancer].
Topics: Animals; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Dogs; Humans; Infusions, Intra-Arterial; Intraoperative Care; Lymph Nodes; Matched-Pair Analysis; Platinum; Rats; Stomach Neoplasms; Survival Rate | 1998 |
[Pharmacokinetics of cis-diammine (glycolato) platinum (254-S), a new platinum antitumor agent, following an intravenous and intraperitoneal infusion bioactive platinum concentration profile].
Topics: Aged; Antineoplastic Agents; Biological Assay; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Organoplatinum Compounds; Peritonitis; Platinum; Stomach Neoplasms; Uterine Cervical Neoplasms | 1990 |
[Clinical study of platinum accumulation in gastric cancer after preoperative intra-arterial injection of cisplatin].
Topics: Cisplatin; Combined Modality Therapy; Female; Gastric Mucosa; Humans; Injections, Intra-Arterial; Injections, Intravenous; Lymph Nodes; Male; Middle Aged; Platinum; Preoperative Care; Stomach Neoplasms; Tissue Distribution | 1989 |
Some preliminary observations during the phase I clinical testing of cis-dichlorodiammineplatinum. II.
Topics: Adult; Amines; Breast Neoplasms; Carcinoma, Bronchogenic; Chlorides; Evaluation Studies as Topic; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Platinum; Stomach Neoplasms | 1973 |